Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Early Rheumatoid Arthritis
NCT00396812Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2006
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in rheumatoid arthritis (RA), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Disease Activity Score-Erythrocyte Sedimentation Rate at 48 weeks. Started Nov 2006; status: terminated.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00396812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396812.